Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Clinical Pharmacology & Therapeutics2017Vol. 103(2), pp. 210–216
Citations Over TimeTop 1% of 2017 papers
Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia M. Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab
Abstract
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
Related Papers
- → Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*(1995)88 cited
- Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.(1998)
- Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.(1999)
- → Tumor Tailored Chemotherapy for Colorectal Cancer in Terms of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase.(2000)4 cited
- [5-fluorouracil and dihydropyrimidine dehydrogenase].(2001)